Zacks Research Brokers Boost Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at Zacks Research increased their Q1 2025 EPS estimates for Sarepta Therapeutics in a research report issued on Tuesday, September 17th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $2.04 per share for the quarter, up from their previous estimate of $1.78. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.47 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.35 EPS, Q3 2025 earnings at $2.30 EPS, Q4 2025 earnings at $2.36 EPS and FY2025 earnings at $9.05 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s revenue was up 38.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.27) earnings per share.

Other equities research analysts also recently issued research reports about the company. Bank of America raised their price target on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a report on Friday, June 21st. UBS Group boosted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Sarepta Therapeutics in a report on Friday, September 6th. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, BMO Capital Markets upped their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research report on Monday, June 24th. Three analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $187.39.

Sarepta Therapeutics Stock Down 0.5 %

Sarepta Therapeutics stock opened at $125.01 on Thursday. The business has a fifty day moving average price of $138.75 and a 200-day moving average price of $132.67. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $173.25. The stock has a market capitalization of $11.82 billion, a price-to-earnings ratio of 1,136.45 and a beta of 0.81. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares in the last quarter. GAMMA Investing LLC increased its stake in Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares in the last quarter. EP Wealth Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after acquiring an additional 103 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Sarepta Therapeutics by 1.9% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after acquiring an additional 120 shares in the last quarter. Finally, WCM Investment Management LLC lifted its position in shares of Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after acquiring an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity

In related news, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The disclosure for this sale can be found here. Insiders sold a total of 52,801 shares of company stock valued at $8,399,586 in the last three months. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.